Viking Global Investors
Viking Global Investors is a long/short equity hedge fund. The fund employs a bottom-up fundamental stock-picking strategy for its investments in equities in the U.S. and Europe. It focuses on the financial, telecommunication, media, technology, and consumer sectors. Viking Global Investors is based in New York and was founded in October, 1999 by Andreas Halvorsen, David Ott, and Brian Olson.
Messers. Halvorsen, Ott, and Olson worked together at Tiger Management Corp. All three left Tiger in early 1999.
View Older Stories View More Recent Stories
-
Ayana Bio Awarded National Institutes of Health Grant to Harness Neuroprotective Benefits from Plant Cell-Cultivated Saffron
-
Mythic Therapeutics Announces Publication of Preclinical Data Highlighting the Differentiating Properties of MYTX-011 in Molecular Cancer Therapeutics
-
Revive Environmental’s PFAS Annihilator® Fit to Destroy PFAS as Outlined by New Environmental Protection Agency (EPA) Guidelines
-
Mythic Therapeutics Presents Preclinical Data on MYTX-011, an Investigational cMET-Targeting Antibody-Drug Conjugate (ADC), at the American Association for Cancer Research (AACR) Annual Meeting
-
Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a New Approach to Discovering and Developing Agonist Antibodies to Tackle the Underlying Causes of Severely Debilitating Diseas
-
Mythic Therapeutics Appoints George Eliades, Ph.D., as President and Chief Executive Officer
-
Form SC 13G/A STANDARD BIOTOOLS INC. Filed by: VIKING GLOBAL INVESTORS LP
-
Form 3 STANDARD BIOTOOLS INC. For: Mar 18 Filed by: Viking Global Opportunities Illiquid Investments Sub-Master LP
-
Battelle and Revive Environmental Technologies Officials Join Ohio Governor Mike DeWine to Announce Kickoff of PFAS Takeback Program
-
Standard BioTools (LAB) exchanged all outstanding shares of its Series B Convertible Preferred Stock for shares of common stock
-
Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock
-
Pearl Health and Wellcare Announce Partnership to Advance Value-Based Care Access in Primary Care
-
Sionna Therapeutics Announces $182 Million Series C Financing to Advance Clinical Development of Novel Small Molecules in Cystic Fibrosis
-
Form SC 13G/A APi Group Corp Filed by: VIKING GLOBAL INVESTORS LP
-
APi Group Corp (APG) Announces Pricing of Upsized Secondary Public Offering of Common Stock
-
APi Group Announces Pricing of Upsized Secondary Public Offering of Common Stock
-
Form 4 RayzeBio, Inc. For: Feb 26 Filed by: VIKING GLOBAL INVESTORS LP
-
Form 4 RayzeBio, Inc. For: Feb 26 Filed by: Viking Global Opportunities Drawdown Portfolio GP LLC
-
Form SC 13G/A RayzeBio, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
APi Group Corporation (APG) Launches 8.13M Share Secondary Offering
-
APi Group Announces Launch of Secondary Public Offering of Common Stock
-
APi Group Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Agreement to Retire All Outstanding Series B Preferred Stock from Blackstone and Viking
-
Mainstay Medical Announces US$125 Million Equity Financing Transaction
-
Areteia Therapeutics Announces Appointment of Daniel Becker, M.D., Ph.D. To Board of Directors
-
Form 13F-HR VIKING GLOBAL INVESTORS For: Dec 31
-
Form SC 13G/A Pharvaris N.V. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Edgewise Therapeutics, Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A APi Group Corp Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Amylyx Pharmaceuticals, Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Adaptive Biotechnologies Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Trevi Therapeutics, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Roivant Sciences Ltd. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Rallybio Corp Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A PepGen Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Ginkgo Bioworks Holdings Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A VALVOLINE INC Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Viking Therapeutics, Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A NewAmsterdam Pharma Co Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Five9, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Inhibrx, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Verastem, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Areteia Therapeutics Announces Additional $75MM in Series A Financing for Oral Dexpramipexole in Eosinophilic Asthma
-
Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders
-
Form SC 13D/A Cazoo Group Ltd Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G Oric Pharmaceuticals, Filed by: VIKING GLOBAL INVESTORS LP
-
Ayana Bio and Wooree Green Science Partner to Develop Plant-Cell Derived Saffron for Health & Wellness Products
-
ORIC Pharmaceuticals (ORIC) Prices 12.5M Share Offering at $10/sh
-
ORIC Pharmaceuticals Announces $125 Million Private Placement Financing
-
Valsoft Corporation Raises Funding to Accelerate Growth in Vertical Market Software
-
Form SC 13G STANDARD BIOTOOLS INC. Filed by: VIKING GLOBAL INVESTORS LP

